CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

Neoadjuvant, Adjuvant Nivolumab Improve EFS in Resectable NSCLC

Table of Contents page: Annals of Oncology

Cancers, Free Full-Text

Keytruda wins second place in the race to approval for neo

The Era of Neoadjuvant Immunotherapy in Resectable Non–Small Cell

Canakinumab with and without pembrolizumab in patients with

Adding Adjuvant Nivolumab Builds on Standard of Care for

Bristol Myers Squibb Announces Perioperative Regimen of

Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and

Nivolumab regimen improves outcomes in resectable non-small cell